A highly protective malaria vaccine would greatly facilitate the prevention and elimination of
malaria and containment of drug-resistant parasites 1 . A high level (more than 90%) of …

RTS,S/AS01E has been tested in a phase 3 malaria vaccine study with partial efficacy in
African children and infants. In a cohort of 1028 subjects from one low (Bagomoyo) and two …

Infection with Plasmodium can elicit antibodies that inhibit parasite survival in the mosquito,
when they are ingested in an infectious blood meal. Here, we determine the transmission-…

An effective vaccine is needed for the prevention and elimination of malaria. The only
immunogens that have been shown to have a protective efficacy of more than 90% against human …

Background Controlled human malaria infection (CHMI) by mosquito bite is a powerful tool
for evaluation of vaccines and drugs against Plasmodium falciparum malaria. However, only …

Characterizing the immune response to pneumococcal proteins is critical in understanding
this bacterium’s epidemiology and vaccinology. Probing a custom-designed proteome …

There is no vaccine to protect from cryptosporidiosis, a leading cause of diarrhea in infants
in low- and middle-income countries. Here, we comprehensively identified parasite antigens …

Naturally acquired immunity (NAI) to Plasmodium falciparum malaria is mainly mediated by
IgG antibodies but the subclasses, epitope targets and effector functions have not been …

Background The RTS,S/AS01E vaccine provides partial protection against malaria in African
children, but immune responses have only been partially characterized and do not reliably …

Children from low- and middle-income countries, where there is a high incidence of infectious
disease, have the greatest need for the protection afforded by vaccination, but vaccines …